Publications

Faculty Publications

Interferon stimulated gene 15 (ISG15) in cancer: An update. Nguyen HM, Gaikwad S, Oladejo M, Agrawal MY, Srivastava SK, Wood LM.Cancer Lett. 2023 Mar 1;556:216080. doi: 10.1016/j.canlet.2023.216080. Epub 2023 Feb 1. PMID: 36736853
Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines. Oladejo M, Paulishak W, Wood L. Semin Cancer Biol. 2023 Jan;88:81-95. doi: 10.1016/j.semcancer.2022.12.003. Epub 2022 Dec 13. PMID: 36526110
Dynamic tumor microenvironment, molecular heterogeneity, and distinct immunologic portrait of triple-negative breast cancer: an impact on classification and treatment approaches. Nguyen HM, Paulishak W, Oladejo M, Wood L. Breast Cancer. 2023 Mar;30(2):167-186. doi: 10.1007/s12282-022-01415-4. Epub 2022 Nov 18.PMID: 36399321
Tumoral CD105 promotes immunosuppression, metastasis, and angiogenesis in renal cell carcinoma. Oladejo M, Nguyen HM, Seah H, Datta A, Wood LM.Cancer Immunol Immunother. 2023 Jun;72(6):1633-1646. doi: 10.1007/s00262-022-03356-5. Epub 2022 Dec 31.PMID: 36586013
Targeting Ubiquitin-like Protein, ISG15, as a Novel Tumor Associated Antigen in Colorectal Cancer. Nguyen HM, Gaikwad S, Oladejo M, Paulishak W, Wood LM.Cancers (Basel). 2023 Feb 15;15(4):1237. doi: 10.3390/cancers15041237.PMID: 36831577
CD105 in the progression and therapy of renal cell carcinoma. Oladejo M, Nguyen HM, Wood L. Cancer Lett. 2023 Jul 25:216327. doi: 10.1016/j.canlet.2023.216327. Online ahead of print.PMID: 37499740
Effects of Volatile Anesthetics versus Ketamine on Blood-Brain Barrier Permeability via Lipid-Mediated Alterations of Endothelial Cell Membranes. Noorani B, Chowdhury EA, Alqahtani F, Ahn Y, Nozohouri E, Zoubi S, Patel D, Wood L, Huang J, Siddique MB, Al-Ahmad A, Mehvar R, Bickel U.J Pharmacol Exp Ther. 2023 May;385(2):135-145. doi: 10.1124/jpet.122.001281. Epub 2023 Feb 24.PMID: 36828631
Influence of adrenalectomy on the gut microbiome and MDMA-induced hyperthermia. Aburahma A, Rana S, Larsen R, Ward CS, Sprague JE.Eur J Pharmacol. 2023 Apr 15;945:175643. doi: 10.1016/j.ejphar.2023.175643. Epub 2023 Mar 5.PMID: 36882148
Upregulation of acid ceramidase contributes to tumor progression in tuberous sclerosis complex. Astrinidis A, Li C, Zhang EY, Zhao X, Zhao S, Guo M, Olatoke T, Mattam U, Huang R, Zhang AG, Pitstick L, Kopras EJ, Gupta N, Jandarov R, Smith EP, Fugate E, Lindquist D, Markiewski MM, Karbowniczek M, Wikenheiser-Brokamp KA, Setchell KDR, McCormack FX, Xu Y, Yu JJ.JCI Insight. 2023 May 8;8(9):e166850. doi: 10.1172/jci.insight.166850.PMID: 36927688
Single-cell multiomic analysis identifies a HOX-PBX gene network regulating the survival of lymphangioleiomyomatosis cells. Olatoke T, Wagner A, Astrinidis A, Zhang EY, Guo M, Zhang AG, Mattam U, Kopras EJ, Gupta N, Smith EP, Karbowniczek M, Markiewski MM, Wikenheiser-Brokamp KA, Whitsett JA, McCormack FX, Xu Y, Yu JJ.Sci Adv. 2023 May 10;9(19):eadf8549. doi: 10.1126/sciadv.adf8549. Epub 2023 May 10.PMID: 37163604
Special issue: Modulation of immune checkpoint proteins and their networks in cancer progression. Srivastava SK, Kim SH. Semin Cancer Biol. 2023 Aug;93:1-2. doi: 10.1016/j.semcancer.2023.04.001. Epub 2023 Apr 7.PMID: 37031897
Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies. Anderson KG, Braun DA, Buqué A, Gitto SB, Guerriero JL, Horton B, Keenan BP, Kim TS, Overacre-Delgoffe A, Ruella M, Triplett TA, Veeranki O, Verma V, Zhang F.J Immunother Cancer. 2023 Jun;11(6):e006533. doi: 10.1136/jitc-2022-006533.PMID: 37399356
Elucidating the direct effects of the novel HDAC inhibitor bocodepsin (OKI-179) on T cells to rationally design regimens for combining with immunotherapy. Holay N, Somma A, Duchow M, Soleimani M, Capasso A, Kottapalli S, Rios J, Giri U, Diamond J, Schreiber A, Piscopio AD, Van Den Berg C, Eckhardt SG, Triplett TA.
Listeria-based vaccination against the pericyte antigen RGS5 elicits anti-vascular effects and colon cancer protection. Anderson TS, McCormick AL, Daugherity EA, Oladejo M, Okpalanwaka IF, Smith SL, Appiah D, Wood LM, Lowe DB. OncoImmunology. 2023 Sep 28;12(1):2260620. doi: 10.1080/2162402X.2023.2260620. eCollection 2023.PMID: 37781234
Pegylated Liposomal Alendronate Biodistribution, Immune Modulation, and Tumor Growth Inhibition in a Murine Melanoma Model. Islam MR, Patel J, Back PI, Shmeeda H, Kallem RR, Shudde C, Markiewski M, Putnam WC, Gabizon AA, La-Beck NM. Biomolecules. 2023 Aug 26;13(9):1309. doi: 10.3390/biom13091309.PMID: 37759709
Targeting the pericyte antigen DLK1 with an alpha type-1 polarized dendritic cell vaccine results in tumor vascular modulation and protection against colon cancer progression. McCormick AL, Anderson TS, Daugherity EA, Okpalanwaka IF, Smith SL, Appiah D, Lowe DB. Front Immunol. 2023 Oct 2;14:1241949. doi: 10.3389/fimmu.2023.1241949. eCollection 2023.PMID: 37849752

The evolution legacy of immune checkpoint inhibitors. Kaushik I, Ramachandran S, Zabel C, Gaikwad S, Srivastava SK. Semin Cancer Biol. 2022 Mar 24:S1044-579X(22)00076-1. doi: 10.1016/j.semcancer.2022.03.020. PMID: 35341912
Immune checkpoint proteins: Signaling mechanisms and molecular interactions in cancer immunotherapy. Gaikwad S, Agrawal MY, Kaushik I, Ramachandran S, Srivastava SK. Semin Cancer Biol. 2022 Mar 24:S1044-579X(22)00070-0. doi: 10.1016/j.semcancer.2022.03.014. PMID: 35341913
GABAA receptor agonist suppresses pediatric medulloblastoma progression by inhibiting PKA-Gli1 signaling axis. Kaushik I, Srivastava SK. Mol Ther. 2022 Jul 6;30(7):2584-2602. doi: 10.1016/j.ymthe.2022.03.012. Epub 2022 Mar 21. PMID: 35331907
Disrupting cancer angiogenesis and immune checkpoint networks for improved tumor immunity. Anderson TS, Wooster AL, Piersall SL, Okpalanwaka F, Lowe D. DOI: 10.1016/j.semcancer.2022.02.009. PMID: 35149179
Research Trend and Detailed Insights into the Molecular Mechanisms of Food Bioactive Compounds against Cancer: A Comprehensive Review with Special Emphasis on Probiotics. Agrawal MY, Gaikwad S, Srivastava S, Srivastava SK. doi: 10.3390/cancers14225482. PMID: 36428575
Inside-Out of Complement in Cancer. Kolev M, Das M, Gerber M, Baver S, Deschatelets P, Markiewski MM. doi: 10.3389/fimmu.2022.931273. eCollection 2022. PMID: 35860237
Listeria-based immunotherapy directed against CD105 exerts antiangiogenic and anti-tumor efficacy in renal cell carcinoma. Oladejo M, Nguyen HM, Silwal A, Reese B, Paulishak W, Markiewski MM, Wood LM. doi: 10.3389/fimmu.2022.1038807. eCollection 2022. PMID: 36439126
A Listeria-based vaccine targeting ISG15 exerts anti-tumor efficacy in renal cell carcinoma. Nguyen HM, Oladejo M, Paulishak W, Wood LM. doi: 10.1007/s00262-022-03352-9. PMID: 36562824.
Tumoral CD105 promotes immunosuppression, metastasis, and angiogenesis in renal cell carcinoma. Oladejo M, Nguyen HM, Seah H, Datta A, Wood LM. doi: 10.1007/s00262-022-03356-5. PMID: 36586013.
Dynamic tumor microenvironment, molecular heterogeneity, and distinct immunologic portrait of triple-negative breast cancer: an impact on classification and treatment approaches. Nguyen HM, Paulishak W, Oladejo M, Wood L. doi: 10.1007/s12282-022-01415-4. PMID: 36399321.
Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines. Oladejo M, Paulishak W, Wood L. doi: 10.1016/j.semcancer.2022.12.003. PMID: 36526110
Comparative effects of free doxorubicin, liposome encapsulated doxorubicin and liposome co-encapsulated alendronate and doxorubicin (PLAD) on the tumor immunologic milieu in a mouse fibrosarcoma model Md Rakibul Islam 1, Jalpa Patel 1, Patricia Ines Back 1, Hilary Shmeeda 2, Konstantin Adamsky 3, Hui Yang 4, Carlos Alvarez 4, Alberto A Gabizon 2 3, Ninh M La-Beck 1 4 PMID: 36105861
Longitudinal COVID-19 immune trajectories in patients with neurological autoimmunity on anti-CD20 therapy. Bazzi SA, Maguire C, Holay N, Geltman J, Hurley K, DiPasquale C, Abigania M, Olson E, Ehrlich LIR, Triplett TA, Melamed E. Mult Scler Relat Disord. 2022 Dec;68:104195. doi: 10.1016/j.msard.2022.104195. Epub 2022 Sep 26.PMID: 36223705
Covalent JNK Inhibitor, JNK-IN-8, Suppresses Tumor Growth in Triple-Negative Breast Cancer by Activating TFEB- and TFE3-Mediated Lysosome Biogenesis and Autophagy. Soleimani M, Somma A, Kaoud T, Goyal R, Bustamante J, Wylie DC, Holay N, Looney A, Giri U, Triplett T, Dalby K, Kowalski J, Eckhardt SG, Van Den Berg C.Mol Cancer Ther. 2022 Oct 7;21(10):1547-1560. doi: 10.1158/1535-7163.MCT-21-1044.PMID: 35977156

Repurposing amino-bisphosphonates by liposome formulation for a new role in cancer treatment.La-Beck NM, Liu X, Shmeeda H, Shudde C, Gabizon AA. Semin Cancer Biol. 2021 Jan;68:175-185. doi: 10.1016/j.semcancer.2019.12.001. Epub 2019 Dec 23.PMID: 31874280
Nanoparticle-Induced Complement Activation: Implications for Cancer Nanomedicine.La-Beck NM, Islam MR, Markiewski MM.Front Immunol. 2021 Jan 8;11:603039. doi: 10.3389/fimmu.2020.603039. eCollection 2020.PMID: 33488603
Antibody-drug conjugates: an evolving approach for melanoma treatment.Anderson TS, Wooster AL, La-Beck NM, Saha D, Lowe DB.Melanoma Res. 2021 Feb 1;31(1):1-17. doi: 10.1097/CMR.0000000000000702.PMID: 33165241
Dendritic cell vaccine therapy for colorectal cancer.Wooster AL, Girgis LH, Brazeale H, Anderson TS, Wood LM, Lowe DB. Pharmacol Res. 2021 Feb;164:105374. doi: 10.1016/j.phrs.2020.105374. Epub 2020 Dec 28.PMID: 33348026
Pathogenetic Features and Current Management of Glioblastoma.Nguyen HM, Guz-Montgomery K, Lowe DB, Saha D.Cancers (Basel). 2021 Feb 18;13(4):856. doi: 10.3390/cancers13040856.PMID: 33670551
The Current State of Oncolytic Herpes Simplex Virus for Glioblastoma Treatment.Nguyen HM, Saha D. Oncolytic Virother. 2021 Feb 24;10:1-27. doi: 10.2147/OV.S268426. eCollection 2021.PMID: 33659221
Repurposing antipsychotics of the diphenylbutylpiperidine class for cancer therapy.Shaw V, Srivastava S, Srivastava SK. Semin Cancer Biol. 2021 Jan;68:75-83. doi: 10.1016/j.semcancer.2019.10.007. Epub 2019 Oct 13.PMID: 31618686
Special issue: Drug repurposing for cancer therapy.Srivastava SK. Semin Cancer Biol. 2021 Jan;68:1-2. doi: 10.1016/j.semcancer.2020.07.008. Epub 2020 Jul 15.PMID: 32679189

The Role of Complement in Angiogenesis.Markiewski MM, Daugherity E, Reese B, Karbowniczek M.Antibodies (Basel). 2020 Dec 1;9(4):67. doi: 10.3390/antib9040067.PMID: 33271774 Free PMC article. Review.
Therapeutic Targeting of Vasculature in the Pre-metastatic and Metastatic Niches Reduces Lung Metastasis.Ghouse SM, Vadrevu SK, Manne S, Reese B, Patel J, Patel B, Silwal A, Lodhi N, Paterson Y, Srivastava SK, Karbowniczek M, Markiewski MM.J Immunol. 2020 Feb 15;204(4):990-1000. doi: 10.4049/jimmunol.1901208. Epub 2020 Jan 3.PMID: 31900334
Complement as Prognostic Biomarker and Potential Therapeutic Target in Renal Cell Carcinoma.Reese B, Silwal A, Daugherity E, Daugherity M, Arabi M, Daly P, Paterson Y, Woolford L, Christie A, Elias R, Brugarolas J, Wang T, Karbowniczek M, Markiewski MM.J Immunol. 2020 Dec 1;205(11):3218-3229. doi: 10.4049/jimmunol.2000511. Epub 2020 Nov 6.PMID: 33158953
Translational considerations in nanomedicine: The oncology perspective.Gabizon AA, de Rosales RTM, La-Beck NM.Adv Drug Deliv Rev. 2020;158:140-157. doi: 10.1016/j.addr.2020.05.012. Epub 2020 Jun 9.PMID: 32526450
Optimizing Patient Outcomes with PD-1/PD-L1 Immune Checkpoint Inhibitors for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer.La-Beck NM, Nguyen DT, Le AD, Alzghari SK, Trinh ST.Pharmacotherapy. 2020 Mar;40(3):239-255. doi: 10.1002/phar.2364. Epub 2020 Jan 29.PMID: 31930528
Thermodynamic Surface Analyses to Inform Biofilm Resistance.Cavitt TB, Carlisle JG, Dodds AR, Faulkner RA, Garfield TC, Ghebranious VN, Hendley PR, Henry EB, Holt CJ, Lowe JR, Lowry JA, Oskin DS, Patel PR, Smith D, Wei W. iScience. 2020 Oct 20;23(11):101702. doi: 10.1016/j.isci.2020.101702. eCollection 2020 Nov 20.PMID: 33205020
Editorial: The Role of Complement in Tumors.Rolfe BE, Pio R, Woodruff TM, Markiewski MM, Manthey HD.Front Immunol. 2020 Feb 11;11:139. doi: 10.3389/fimmu.2020.00139. eCollection 2020.PMID: 32117286
Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy.Nguyen HM, Guz-Montgomery K, Saha D.Cells. 2020 Feb 10;9(2):400. doi: 10.3390/cells9020400.PMID: 32050597
Oncolytic Herpes Simplex Virus Encoding IL12 Controls Triple-Negative Breast Cancer Growth and Metastasis.Ghouse SM, Nguyen HM, Bommareddy PK, Guz-Montgomery K, Saha D.Front Oncol. 2020 Mar 24;10:384. doi: 10.3389/fonc.2020.00384. eCollection 2020.PMID: 32266155
Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma.Saha D, Rabkin SD, Martuza RL.J Immunother Cancer. 2020 May;8(1):e000345. doi: 10.1136/jitc-2019-000345.PMID: 32457126
Immunohistochemistry for Tumor-Infiltrating Immune Cells After Oncolytic Virotherapy.Saha D, Rabkin SD.Methods Mol Biol. 2020;2058:179-190. doi: 10.1007/978-1-4939-9794-7_11.PMID: 31486038
Cancer cells stemness: A doorstep to targeted therapy.Prasad S, Ramachandran S, Gupta N, Kaushik I, Srivastava SK. Biochim Biophys Acta Mol Basis Dis. 2020 Apr 1;1866(4):165424. doi: 10.1016/j.bbadis.2019.02.019. Epub 2019 Feb 26.PMID: 30818002
Oxidative Stress and Cancer: Chemopreventive and Therapeutic Role of Triphala.Prasad S, Srivastava SK.Antioxidants (Basel). 2020 Jan 13;9(1):72. doi: 10.3390/antiox9010072.PMID: 31941067
Drug rechanneling: A novel paradigm for cancer treatment.Kaushik I, Ramachandran S, Prasad S, Srivastava SK. Semin Cancer Biol. 2021 Jan;68:279-290. doi: 10.1016/j.semcancer.2020.03.011. Epub 2020 May 11.PMID: 32437876 Review
Low Dose of Penfluridol Inhibits VEGF-Induced Angiogenesis.Srivastava S, Zahra FT, Gupta N, Tullar PE, Srivastava SK, Mikelis CM.Int J Mol Sci. 2020 Jan 23;21(3):755. doi: 10.3390/ijms21030755.PMID: 31979394
Pimozide Suppresses the Growth of Brain Tumors by Targeting STAT3-Mediated Autophagy.Ranjan A, Kaushik I, Srivastava SK.Cells. 2020 Sep 22;9(9):2141. doi: 10.3390/cells9092141.PMID: 32971907

The Codon 72 TP53 Polymorphism Contributes to TSC Tumorigenesis through the Notch-Nodal Axis. Cho JH, Patel B, Bonala S, Mansouri H, Manne S, Vadrevu SK, Ghouse S, Kung CP, Murphy ME, Astrinidis A, Henske, Kwiatkowski DJ, Markiewski MM, Karbowniczek M. Mol Cancer Res. 2019 Aug: 17(8): 1639-1651. doi: 10.1158/1541-7786. MCR-18-1292. Epub 2019 May 14.
Harnessing Liposome Interactions With the Immune System for the Next Breakthrough in Cancer Drug Delivery.La-Beck NM, Liu X, Wood LM.Front Pharmacol. 2019 Mar 12;10:220. doi: 10.3389/fphar.2019.00220. eCollection 2019.PMID: 30914953
Multi-parametric flow cytometry staining procedure for analyzing tumor-infiltrating immune cells following oncolytic herpes simplex virus immunotherapy in intracranial glioblastoma.Bommareddy PK, Lowe DB, Kaufman HL, Rabkin SD, Saha D.J Biol Methods. 2019;6(2):e112. doi: 10.14440/jbm.2019.281. Epub 2019 Apr 4.PMID: 31123687
Expression and characterization of soluble epitope-defined major histocompatibility complex (MHC) from stable eukaryotic cell lines.Wooster AL, Anderson TS, Lowe DB.J Immunol Methods. 2019 Jan;464:22-30. doi: 10.1016/j.jim.2018.10.006. Epub 2018 Oct 19.PMID: 30347189
Multi-parametric flow cytometry staining procedure for analyzing tumor-infiltrating immune cells following oncolytic herpes simplex virus immunotherapy in intracranial glioblastoma.Bommareddy PK, Lowe DB, Kaufman HL, Rabkin SD, Saha D.J Biol Methods. 2019;6(2):e112. doi: 10.14440/jbm.2019.281. Epub 2019 Apr 4.PMID: 31123687
Triple combination immunotherapy with GVAX, anti-PD-1 monoclonal antibody, and agonist anti-OX40 monoclonal antibody is highly effective against murine intracranial glioma.Jahan N, Talat H, Alonso A, Saha D, Curry WT. Oncolmmunology. 2019 Feb 27;8(5):e1577108. doi: 10.1080/2162402X.2019.1577108. eCollection 2019.PMID: 31069135
Role of Phytochemicals in Cancer Prevention.Ranjan A, Ramachandran S, Gupta N, Kaushik I, Wright S, Srivastava S, Das H, Srivastava S, Prasad S, Srivastava SK.Int J Mol Sci. 2019 Oct 9;20(20):4981. doi: 10.3390/ijms20204981.PMID: 31600949
CRISPR-Cas9: A multifaceted therapeutic strategy for cancer treatment.Kaushik I, Ramachandran S, Srivastava SK. Semin Cell Dev Biol. 2019 Dec;96:4-12. doi: 10.1016/j.semcdb.2019.04.018. Epub 2019 May 4.PMID: 31054324
Penfluridol overcomes paclitaxel resistance in metastatic breast cancer.Gupta N, Gupta P, Srivastava SK.Sci Rep. 2019 Mar 25;9(1):5066. doi: 10.1038/s41598-019-41632-0.PMID: 30911062
Atovaquone: An Antiprotozoal Drug Suppresses Primary and Resistant Breast Tumor Growth by Inhibiting HER2/β-Catenin Signaling.Gupta N, Srivastava SK.Mol Cancer Ther. 2019 Oct;18(10):1708-1720. doi: 10.1158/1535-7163.MCT-18-1286. Epub 2019 Jul 3.PMID: 31270151
HER2-mediated GLI2 stabilization promotes anoikis resistance and metastasis of breast cancer cells.Gupta P, Gupta N, Fofaria NM, Ranjan A, Srivastava SK.Cancer Lett. 2019 Feb 1;442:68-81. doi: 10.1016/j.canlet.2018.10.021. Epub 2018 Oct 26.PMID: 30409762

Complementing Cancer Metastasis.Kochanek DM, Ghouse SM, Karbowniczek MM, Markiewski MM.Front Immunol. 2018 Jul 16;9:1629. doi: 10.3389/fimmu.2018.01629. eCollection 2018.PMID: 30061895 Free PMC article. Review.
Targeting complement-mediated immunoregulation for cancer immunotherapy.Kolev M, Markiewski MM. Semin Immunol. 2018 Jun;37:85-97. doi: 10.1016/j.smim.2018.02.003. Epub 2018 Feb 15.PMID: 29454575
Role of Forkhead Box Class O proteins in cancer progression and metastasis.Kim CG, Lee H, Gupta N, Ramachandran S, Kaushik I, Srivastava S, Kim SH, Srivastava SK. Semin Cancer Biol. 2018 Jun;50:142-151. doi: 10.1016/j.semcancer.2017.07.007. Epub 2017 Aug 1.PMID: 28774834
AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells.Verma K, Gupta N, Zang T, Wangtrakluldee P, Srivastava SK, Penning TM, Trippier PC.Mol Cancer Ther. 2018 Sep;17(9):1833-1845. doi: 10.1158/1535-7163.MCT-17-1023. Epub 2018 Jun 11.PMID: 29891491
Zinc finger protein 746 promotes colorectal cancer progression via c-Myc stability mediated by glycogen synthase kinase 3β and F-box and WD repeat domain-containing 7.Jung JH, Jung DB, Kim H, Lee H, Kang SE, Srivastava SK, Yun M, Kim SH.Oncogene. 2018 Jul;37(27):3715-3728. doi: 10.1038/s41388-018-0225-0. Epub 2018 Apr 9.PMID: 29628506
Regulation of SIRT1/AMPK axis is critically involved in gallotannin-induced senescence and impaired autophagy leading to cell death in hepatocellular carcinoma cells.Kwon HY, Kim JH, Kim B, Srivastava SK, Kim SH.Arch Toxicol. 2018 Jan;92(1):241-257. doi: 10.1007/s00204-017-2021-y. Epub 2017 Jul 4.PMID: 28676953

Notch transactivates Rheb to maintain the multipotency of TSC-null cells.Cho JH, Patel B, Bonala S, Manne S, Zhou Y, Vadrevu SK, Patel J, Peronaci M, Ghouse S, Henske EP, Roegiers F, Giannikou K, Kwiatkowski DJ, Mansouri H, Markiewski MM, White B, Karbowniczek M. Nat Commun. 2017 Nov 29;8(1):1848. doi: 10.1038/s41467-017-01845-1.PMID: 29184052
The Ribosomal Protein S19 Suppresses Antitumor Immune Responses via the Complement C5a Receptor 1.Markiewski MM, Vadrevu SK, Sharma SK, Chintala NK, Ghouse S, Cho JH, Fairlie DP, Paterson Y, Astrinidis A, Karbowniczek M.J Immunol. 2017 Apr 1;198(7):2989-2999. doi: 10.4049/jimmunol.1602057. Epub 2017 Feb 22.PMID: 28228558
Management of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: a Minireview of Current Clinical Guidelines.Trinh S, Le A, Gowani S, La-Beck NM.Asia Pac J Oncol Nurs. 2019 Apr-Jun;6(2):154-160. doi: 10.4103/apjon.apjon_3_19.PMID: 30931360
Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context.Le AD, Alzghari SK, Jean GW, La-Beck NM. Ther Clin Risk Manag. 2017 Feb 21;13:223-236. doi: 10.2147/TCRM.S104343. eCollection 2017.PMID: 28260909
TCR-like antibody drug conjugates mediate killing of tumor cells with low peptide/HLA targets.Lowe DB, Bivens CK, Mobley AS, Herrera CE, McCormick AL, Wichner T, Sabnani MK, Wood LM, Weidanz JA. MAbs. 2017 May/Jun;9(4):603-614. doi: 10.1080/19420862.2017.1302630.PMID: 28273004
Liposome-induced immunosuppression and tumor growth is mediated by macrophages and mitigated by liposome-encapsulated alendronate.Rajan R, Sabnani MK, Mavinkurve V, Shmeeda H, Mansouri H, Bonkoungou S, Le AD, Wood LM, Gabizon AA, La-Beck NM.J Control Release. 2018 Feb 10;271:139-148. doi: 10.1016/j.jconrel.2017.12.023. Epub 2017 Dec 23.PMID: 29277680
Penfluridol suppresses glioblastoma tumor growth by Akt-mediated inhibition of GLI1.Ranjan A, Srivastava SK. Oncotarget. 2017 May 16;8(20):32960-32976. doi: 10.18632/oncotarget.16515.PMID: 28380428
Penfluridol induces endoplasmic reticulum stress leading to autophagy in pancreatic cancer.Ranjan A, German N, Mikelis C, Srivenugopal K, Srivastava SK. Tumour Biol. 2017 Jun;39(6):1010428317705517. doi: 10.1177/1010428317705517.PMID: 28618969
Immune consequences of penfluridol treatment associated with inhibition of glioblastoma tumor growth.Ranjan A, Wright S, Srivastava SK. Oncotarget. 2017 Jul 18;8(29):47632-47641. doi: 10.18632/oncotarget.17425.PMID: 28512255

Exosomes mediate the acquisition of the disease phenotypes by cells with normal genome in tuberous sclerosis complex.Patel B, Patel J, Cho JH, Manne S, Bonala S, Henske E, Roegiers F, Markiewski M, Karbowniczek M. Oncogene. 2016 Jun 9;35(23):3027-36. doi: 10.1038/onc.2015.358. Epub 2015 Oct 5.PMID: 26434588
New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy.Gabizon AA, Patil Y, La-Beck NM.Drug Resist Updat. 2016 Nov;29:90-106. doi: 10.1016/j.drup.2016.10.003. Epub 2016 Oct 29.PMID: 27912846
Penfluridol suppresses pancreatic tumor growth by autophagy-mediated apoptosis.Ranjan A, Srivastava SK.Sci Rep. 2016 May 18;6:26165. doi: 10.1038/srep26165.PMID: 27189859
Nanoemulsion formulations for anti-cancer agent piplartine--Characterization, toxicological, pharmacokinetics and efficacy studies.Fofaria NM, Qhattal HS, Liu X, Srivastava SK.Int J Pharm. 2016 Feb 10;498(1-2):12-22. doi: 10.1016/j.ijpharm.2015.11.045. Epub 2015 Nov 28.PMID: 26642946
Penfluridol: An Antipsychotic Agent Suppresses Metastatic Tumor Growth in Triple-Negative Breast Cancer by Inhibiting Integrin Signaling Axis.Ranjan A, Gupta P, Srivastava SK.Cancer Res. 2016 Feb 15;76(4):877-90. doi: 10.1158/0008-5472.CAN-15-1233. Epub 2015 Dec 1.PMID: 26627008

Pulmonary alveolar macrophages contribute to the pre-metastatic niche by suppressing antitumor T cell responses in the lungs.Sharma SK, Chintala NK, Vadrevu SK, Patel J, Karbowniczek M, Markiewski MM.J Immunol. 2015 Jun 1;194(11):5529-38. doi: 10.4049/jimmunol.1403215. Epub 2015 Apr 24.PMID: 25911761
Quantifying autophagosomes and autolysosomes in cells using imaging flow cytometry.Rajan R, Karbowniczek M, Pugsley HR, Sabnani MK, Astrinidis A, La-Beck NM. Cytometry A. 2015 May;87(5):451-8. doi: 10.1002/cyto.a.22652. Epub 2015 Feb 27.PMID: 25728685
Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.La-Beck NM, Jean GW, Huynh C, Alzghari SK, Lowe DB.Pharmacotherapy. 2015 Oct;35(10):963-76. doi: 10.1002/phar.1643.PMID: 26497482
Ubiquitin-like Molecule ISG15 Acts as an Immune Adjuvant to Enhance Antigen-specific CD8 T-cell Tumor Immunity.Villarreal DO, Wise MC, Siefert RJ, Yan J, Wood LM, Weiner DB, Mol Ther. 2015 Oct;23(10):1653-62. doi: 10.1038/mt.2015.120. Epub 2015 Jun 30.PMID: 26122932
Liposome promotion of tumor growth is associated with angiogenesis and inhibition of antitumor immune responses.Sabnani MK, Rajan R, Rowland B, Mavinkurve V, Wood LM, Gabizon AA, La-Beck NM. Nanomedicine. 2015 Feb;11(2):259-62. doi: 10.1016/j.nano.2014.08.010. Epub 2014 Sep 6.PMID: 25200609
Modulation of signal transduction pathways by natural compounds in cancer.Ranjan A, Fofaria NM, Kim SH, Srivastava SK.Chin J Nat Med. 2015 Oct;13(10):730-42. doi: 10.1016/S1875-5364(15)30073-X.PMID: 26481373
Mechanisms of the Anticancer Effects of Isothiocyanates.Fofaria NM, Ranjan A, Kim SH, Srivastava SK.Enzymes. 2015;37:111-37. doi: 10.1016/bs.enz.2015.06.001. Epub 2015 Jul 7.PMID: 26298458
PEITC treatment suppresses myeloid derived tumor suppressor cells to inhibit breast tumor growth.Gupta P, Wright SE, Srivastava SK. OncoImmunology. 2015 Mar 6;4(2):e981449. doi: 10.4161/2162402X.2014.981449. eCollection 2015 Feb.PMID: 25949878
Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.Fofaria NM, Frederick DT, Sullivan RJ, Flaherty KT, Srivastava SK. Oncotarget. 2015 Dec 1;6(38):40535-56. doi: 10.18632/oncotarget.5755.PMID: 26497853
STAT3 induces anoikis resistance, promotes cell invasion and metastatic potential in pancreatic cancer cells.Fofaria NM, Srivastava SK. Carcinogenesis. 2015 Jan;36(1):142-50. doi: 10.1093/carcin/bgu233. Epub 2014 Nov 19.PMID: 25411359
Inhibition of β-catenin signaling suppresses pancreatic tumor growth by disrupting nuclear β-catenin/TCF-1 complex: critical role of STAT-3.Pramanik KC, Fofaria NM, Gupta P, Ranjan A, Kim SH, Srivastava SK. Oncotarget. 2015 May 10;6(13):11561-74. doi: 10.18632/oncotarget.3427.PMID: 25869100
A derivative of epigallocatechin-3-gallate induces apoptosis via SHP-1-mediated suppression of BCR-ABL and STAT3 signaling in chronic myelogenous leukaemia.Jung JH, Yun M, Choo EJ, Kim SH, Jeong MS, Jung DB, Lee H, Kim EO, Kato N, Kim B, Srivastava SK, Kaihatsu K, Kim SH.Br J Pharmacol. 2015 Jul;172(14):3565-78. doi: 10.1111/bph.13146. Epub 2015 Jun 4.PMID: 25825203

Faculty Patents

Provisional Patent #62963258 Novel and potent JAK/STAT inhibitors.

US10,463,649 - Inhibitors of Mc1-1 as drugs to overcome resistance to BRAF inhibitors and MEK inhibitors.

#PCT/US 2018: 60763 - Composition and methods for treating cancer. (Sanjay K. Srivastava)

Provisional Patent #62585080- Composition and methods for treating cancer. (Sanjay K. Srivastava)

PCT/US2016 #036002 - Inhibitors of Mcl-1 as drugs to overcome resistance to BRAF inhibitors and MEK inhibitors (Sanjay K. Srivastava)

#62/172,327 - Inhibitors of Mcl-1 as drugs to overcome resistance to BRAF inhibitors and MEK inhibitors (Sanjay K. Srivastava)
# 62/189,377 - Formulations of piperlongumine for oral and topical application for prevention and treatment of melanoma (Sanjay K. Srivastava)
#62026970 - Overcoming Chemotherapeutic Agent Resistance in Cancer by Inhibiting Mcl-1 (Sanjay K. Srivastava)

WO2014210411 A1 - Histone deacetylase inhibitors and methods of use (Sanjay K. Srivastava)
#61973672 - Overcoming vemurafenib resistance in metastatic cancers (Sanjay K. Srivastava)
#62026970 - Overcoming chemotherapeutic agent resistance in cancer by inhibiting Mcl-1 (Sanjay K. Srivastava)

#61840751 - Histone deacetylase inhibitors and methods of use (Sanjay K. Srivastava)
WO2013/074820 - Immunogenic tumor associated stromal cell antigen peptides and methods of their use. (WJ Storkus, A. Bose, JL Taylor, X Zhao, DB Lowe)